Contineum Therapeutics, Inc. (CTNM) vs Puma Biotechnology, Inc. (PBYI)
Contineum Therapeutics, Inc. and Puma Biotechnology, Inc. are both Biotechnology companies. Contineum Therapeutics, Inc. and Puma Biotechnology, Inc. are of similar size ($506.9M and $469.9M). Contineum Therapeutics, Inc. has negative trailing earnings, so its P/E is not meaningful; Puma Biotechnology, Inc. trades at 18.1×. Puma Biotechnology, Inc. has the higher net margin (11.6% vs 0.00%) and the higher return on invested capital (42.6% vs −1,334.4%). Across the 12 metrics below, Puma Biotechnology, Inc. leads on 9 and Contineum Therapeutics, Inc. on 3.
Valuation
Profitability
| Metric | CTNM | PBYI | Biotechnology median |
|---|---|---|---|
| Gross margin | — | 74.83% | 65.16% |
| Operating margin | 0.00% | 13.16% | 0.00% |
| Net margin | 0.00% | 11.55% | 0.00% |
| Free cash flow margin | 0.00% | 17.79% | 0.00% |
| Return on equity | (28.01%) | 21.97% | (57.72%) |
| Return on assets | (26.57%) | 13.78% | (49.22%) |
| Return on invested capital | (1,334.41%) | 42.61% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack